When was Curasight founded?

Curasight was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Curasight located?

Curasight is headquartered in Copenhagen, Denmark.

Who is the current CEO of Curasight?

Morten Persson and Ulrich Alexander Krasilnikoff s of Curasight.

Which legal entities is Curasight associated with?

Curasight is associated with Curasight AS.

How many employees does Curasight have?

As of Jul 31, 2026, the latest employee count at Curasight is 6.

Is Curasight a funded company?

Curasight is a funded company, having raised a total of $11.5M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 19, 2014.

How much is Curasight worth?

The latest valuation of Curasight is $***** as of Sep 22, 2020.

When was the latest funding round of Curasight?

Curasight's latest funding was a $***** Series A round on Sep 22, 2020, with participation from 0 investor.

Where does Curasight rank among its competitors?

Curasight ranks 4th amongst 101 active competitors, of which 39 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Mammogen, which secured $30M in Jun, 2026.

Who are the top competitors of Curasight?

Curasight's top competitors include ScreenPoint, PreludeDx and Syantra Health. Among them, Mammogen secured the most recent funding round in June, 2026.

Curasight - 2026 Company Profile, Team, Funding, Competitors & Financials

Curasight is a series A company based in Copenhagen (Denmark), founded in 2013 by Jacob Madsen, Carsten Haagen Nielsen and Morten Persson. It operates as a Developer of PET ligands for breast cancer indications. Curasight has raised $11.5M in funding from PreSeed Ventures, with a current valuation of $*****. The company has 101 active competitors, including 39 funded and 10 that have exited. Its top competitors include companies like ScreenPoint, PreludeDx and Syantra Health.

Company Details

Developer of PET ligands for breast cancer indications. It provides PET imaging target based on the urokinase-type plasminogen activator receptor (uPAR) for breast cancer diagnose. They are focused on developing disease-specific PET ligands for multiple cancer indications.

Key Metrics

Founded Year

2013

Location

Copenhagen, Denmark

Stage

Series A

Total Funding

$11.5M in 4 rounds

Latest Funding Round

Series A, Sep 22, 2020, $*****

Post Money Valuation

$***** as on Sep 22, 2020

Investors

PreSeed Ventures & 1 more

Ranked

4^th among 101 active competitors

Employee Count

6 as on Jul 31, 2026

Similar Companies

ScreenPoint & 138 more

View Curasight's full profile

Curasight is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Curasight AS CIN: 35249389 , Denmark, Active	May 21, 2013	-	9 (As on Nov 30, 2024)

Curasight has raised a total funding of $11.5M over 4 rounds. Its first funding round was on May 19, 2014. Curasight has 2 institutional investors.

Here is the list of recent funding rounds of Curasight:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 22, 2020	9352569	Series A	9479265	5352071	1129866	5568891
Jun 05, 2017	1174270	Seed	8239995	3266030	8320506	1758851
Jun 25, 2015	1070386	Seed	8859112	4956546	1490252	3750003

Access funding benchmarks and valuations. Sign up today!

View details of Curasight's funding rounds and investors

The founders of Curasight are Jacob Madsen, Carsten Haagen Nielsen and Morten Persson. Ulrich Alexander Krasilnikoff is the CEO of Curasight.

Here are the details of Curasight's key team members:

Jacob Madsen: Co-Founder & Director of Curasight.
Carsten Haagen Nielsen: Co-Founder & Director of Curasight.
Morten Persson: Co-Founder & CEO of Curasight.
Ulrich Alexander Krasilnikoff: CEO of Curasight. They serve on the board of 1 company.

Curasight's Board of Directors

Curasight's board has 3 active members. Per Falholt, Charlotte Vedel and Ulrich Alexander Krasilnikoff are independent board members.

Here is the list of Curasight's board of directors:

Name	Type	Representing	Status	Duration
lsnnntg	Team	-	Past	7y 6m
Per Falholt	Independent board member	-	Current	6y 1m
zotjrdn	Independent board member	-	Current	4y 8m
swdgyaf	Independent board member	-	Current	6y 8m
xmlcikt	Independent board member	-	Past	7y 8m

View details of Curasight's Founder profiles and Board Members

Curasight's employee count trend

Curasight has 6 employees as of Jul 26. Here is Curasight's employee count trend over the years:

Uncover Curasight's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Curasight include ScreenPoint, PreludeDx and Syantra Health. Here is the list of Top 10 competitors of Curasight, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ScreenPoint 2014, Nijmegen (Netherlands), Series C	Developer of artificial intelligence software for analyzing breast imaging mammograms	$47M	Siemens, Insight Partners & 3 others	64/100
2nd	PreludeDx 2009, Laguna Hills (United States), Series B	Provider of risk assessment test for early stage breast cancer	$51.7M	Evidity Health Capital, GenesisCare & 2 others	57/100
3rd	Syantra Health 2016, Calgary (Canada), Series A	Developer of a blood test device to detect breast cancer	$10.4M	Plug and Play Tech Center, The51 & 5 others	54/100
4th	Curasight 2013, Copenhagen (Denmark), Series A	Developer of PET ligands for breast cancer indications	$11.5M	PSV Deeptech & 1 others	52/100
5th	Lucerno Dynamics 2011, Cary (United States), Series A	Developer of imaging technology to measure radiotracer quality	$6.34M	NC IDEA, Elevate Innovation Partners & 2 others	51/100
6th	Mammogen 2020, Aliso Viejo (United States), Series A	Developer of a diagnostic test to detect breast cancer	$32M	-	49/100
7th	Isotropic Imaging 2016, Las Vegas (United States), Public	Innovating breast cancer imaging with dedicated 3D breast CT technology	-	-	48/100
8th	OncoStem 2011, Bengaluru (India), Series A	Developer of prognostic tests for the detection of cancer	$9M	Artiman, Peak XV Partners & 1 others	45/100
9th	Biotheranostics 2008, San Diego (United States), Acquired	Commercial stage molecular diagnostics tests tailored to individual cancer patients.	$32M	MVM, Health Quest Capital & 2 others	44/100
10th	MedTrace 2015, Horsholm (Denmark), Series B	Provider of molecular imaging solutions to improve patient outcomes	$66.2M	ATP, Verve Ventures & 4 others	43/100